



Supplemental figures

Supplementary Figure 1




Supplementary Figure 1: Schematic of PDO density quantification using Celigo Image Cytometer Software.

Supplementary Figure 2



Supplementary Figure 2: EAC PDOs serve as avatars for patients' responses to therapy. Relative PDO density in response to components of standard of care and alternative treatment. 2-way ANOVA parameters: P_i =significance of interaction (differential response of organoid lines), P_c =significance of concentration/dose, P_o =significance of organoid line. Error bars = SEM, significant P-values for multiple comparisons are listed on the graphs.




Supplementary Figure 3



Supplementary Figure 3: Introduction of EACorg011 does not substantially alter the DEG lists. DEG lists obtained by analyzing datasets comprised by EACorg000+EACorg006+EACorg001 were plotted against the DEG lists obtained by analyzing the EACorg000+EACorg006 datasets. R^2 values for linear relationship displayed on the graphs.

Supplementary Figure 4

■ EACorg000 ▲ EACorg002 ▼ EACorg006 ◆ EACorg011



Supplementary Figure 4: EAC PDOs respond differentially to experimental therapeutics. Relative PDO density in response to components of standard of care and alternative treatment. 2-way ANOVA parameters: P_i =significance of interaction (differential response of organoid lines), P_c =significance of concentration/dose, P_o =significance of organoid line. Error bars = SEM, significant P-values for multiple comparisons are listed on the graphs.